C3 glomerulopathy: Consensus report

Kidney International

Volumn 84, Issue 6, 2013, Pages 1079-1089

  Pickering, Matthew C ^a   D'agati, Vivette D ^b   Nester, Carla M ^c   Smith, Richard J ^c   Haas, Mark ^d   Appel, Gerald B ^b   Alpers, Charles E ^e   Bajema, Ingeborg M ^f   Bedrosian, Camille ^g   Braun, Michael ^h   Doyle, Mittie ^g   Fakhouri, Fadi ⁱ   Fervenza, Fernando C ^j   Fogo, Agnes B ^k   Frémeaux Bacchi, Véronique ^l   Gale, Daniel P ^m   Goicoechea De Jorge, Elena ^a   Griffin, Gene ^g   Harris, Claire L ⁿ   Holers, V Michael ^o   Johnson, Sally ^p   Lavin, Peter J ^q   Medjeral Thomas, Nicholas ^a   Paul Morgan, B ⁿ   Nast, Cynthia C ^d   Noel, Laure Hélène ^r   Peters, D Keith ^s   Rodríguez De Córdoba, Santiago ^t   Servais, Aude ^u   Sethi, Sanjeev ^j   Song, Wen Chao ^v   Tamburini, Paul ^g   Thurman, Joshua M ^o   Zavros, Michael ^w   Cook, H Terence ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ALEXION PHARMACEUTICALS   (United States)

^h TEXAS CHILDREN S HOSPITAL   (United States)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j MAYO CLINIC   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ CARDIFF UNIVERSITY   (United Kingdom)

^o UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^p Infectious Diseases Allergy   (United Kingdom)

^q ADELAIDE AND MEATH HOSPITAL   (Ireland)

^r INSERM   (France)

^s University of Pennsylvania ^*

^t CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^u HÔPITAL NECKER ENFANTS MALADES   (France)

^v UNIVERSITY OF PENNSYLVANIA   (United States)

^w UNIVERSITY OF CYPRUS   (Cyprus)

more..

Author keywords

clinical immunology; clinical nephrology; complement; glomerulonephritis; immunology and pathology

Indexed keywords

ECULIZUMAB; RITUXIMAB;

CONFERENCE PAPER; CONSENSUS; DRUG EFFECT; DRUG EFFICACY; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; KIDNEY STRUCTURE; KIDNEY TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT DURATION;

BIOMEDICAL RESEARCH; BIOPSY; COMPLEMENT C3; COOPERATIVE BEHAVIOR; GLOMERULONEPHRITIS; HUMANS; INTERNATIONAL COOPERATION; KIDNEY GLOMERULUS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84888641200     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.377     Document Type: Conference Paper

References (34)

1. Fakhouri F, Fremeaux-Bacchi V, Noel LH et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010; 6: 494-499.
2. Martinez-Barricarte R, Heurich M, Valdes-Canedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712.
3. Gale DP, de Jorge EG, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801.
4. Malik TH, Lavin PJ, Goicoechea de Jorge E et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23: 1155-1160.
5. Walker PD, Ferrario F, Joh K et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20: 605-616.
6. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464.
7. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-1237.
8. Hou J, Markowitz GS, Herlitz LC et al. Toward a working definition of C3 Glomerulopathy by immunofluorescence. Kidney Int 2013 (this issue). doi:10.1038/ki.2013.340.
9. Sethi S, Fervenza FC, Zhang Y et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2012; 83: 293-299.
10. Strobel S, Zimmering M, Papp K et al. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010; 47: 1476-1483.
11. Chen Q, Wiesner M, Eberhardt H et al. A novel hybrid CFHR2/CFHR5 gene develops MPGN II and provides insights into disease mechanism and therapeutic implications. Immunobiology 2012; 217: 1131.
12. Tortajada A, Yeaaaabenes H, Abarrategui-Garrido C et al. C3 glomerulopathyassociated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 2013; 123: 2434-2446.
13. Medjeral-Thomas N, Malik TH, Patel MP et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 2013 (this issue).
14. Abrera-Abeleda MA, Nishimura C, Frees K et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551-1559.
15. Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012; 82: 1084-1092.
16. Zhang Y, Meyer NC, Wang K et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012; 7: 265-274.
17. Jokiranta TS, Solomon A, Pangburn MK et al. Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 1999; 163: 4590-4596.
18. Nozal P, Strobel S, Ibernon M et al. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 2012; 5: 133-136.
19. Sethi S, Sukov WR, Zhang Y et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56: 977-982.
20. Sethi S, Zand L, Leung N et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5: 770-782.
21. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: Clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446.
22. Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 2013; 22: 231-237.
23. Appel GB, Cook HT, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 2005; 16: 1392-1403.
24. Group KDIGOKGW. KDIGO Clinical Practice Guideline for Glomerulonphritis. Kidney Int (Suppl) 2012; 2: 198-199.
25. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366: 1161-1163.
26. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant 2012; 12: 1046-1051.
27. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
28. Licht C, Weyersberg A, Heinen S et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45: 415-421.
29. Banks RA, May S, Wallington T. Acute renal failure in dense deposit disease: Recovery after plasmapheresis. Br Med J (Clin Res Ed) 1982; 284: 1874-1875.
30. Krmar RT, Holtback U, Linne T et al. Acute renal failure in dense deposit disease: Complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol 2011; 75(Suppl 1): 4-10.
31. Pickering MC, Warren J, Rose KL et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006; 103: 9649-9654.
32. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366: 1163-1165.
33. Little MA, Dupont P, Campbell E et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006; 69: 504-511.
34. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.